OnKure Therapeutics (NASDAQ:OKUR) Raised to “Strong-Buy” at Lifesci Capital
Lifesci Capital upgraded shares of OnKure Therapeutics (NASDAQ:OKUR – Free Report) to a strong-buy rating in a research report report published on Thursday, Zacks.com reports. Separately, Oppenheimer assumed coverage on shares of OnKure Therapeutics in a research note on Thursday. They set an outperform rating and a $35.00 target price for the company. Get Our […]
13 Oct 11:04 · The Markets Daily